ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 2029

Health-Related Quality of Life in Idiopathic Inflammatory Myopathies: How to Act for Improving the Disease Burden of Patients?

Chiara Cardelli1, Simone Barsotti2, Elenia Laurino1, Michele Diomedi1, Federico Fattorini1, Dina Zucchi3, Alessandra Tripoli1, Linda Carli1 and Marta Mosca1, 1Rheumatology Unit, Department of Clinical and Experimental Medicine, University of Pisa, Pisa, Italy, 2Internal Medicine, Ospedale di Livorno, Pisa, Italy, 3Rheumatology Unit, Department of Clinical and Experimental Medicine, University of Pisa, Italy; Department of Medical Biotechnologies, University of Siena, Pisa, Italy

Meeting: ACR Convergence 2023

Keywords: Comorbidity, Myositis, Patient reported outcomes, quality of care, quality of life

  • Tweet
  • Email
  • Print
Session Information

Date: Tuesday, November 14, 2023

Title: (2019–2038) Patient Outcomes, Preferences, & Attitudes Poster III

Session Type: Poster Session C

Session Time: 9:00AM-11:00AM

Background/Purpose: Idiopathic Inflammatory Myopathies (IIM) are rare, multisystemic and complex diseases that strongly impact the Quality of Life (QoL) of those affected. Patient Reported Outcomes (PROs) are validated tools that assess the overall health status of patients, particularly with regard to emotional and functional domains. The aim of the study was to evaluate the impact of disease clinical features and comorbidities on Health-Related (HR) QoL in a monocentric cohort of IIM patients.

Methods: Consecutive adult patients with a diagnosis of IIM (2017 EULAR/ACR criteria) followed at our Myositis Clinic were enrolled in this cross-sectional study. Demographic and clinical data were collected at enrolment. HRQoL was evaluated by administration of generic PROs: Patient Global Assessment (PGA), Health Assessment Questionnaire (HAQ), Short-Form 36 Items Health Survey (SF36), Functional Assessment of Chronic Illness Therapy Fatigue Subscale (FACIT-F), Hospital Anxiety and Depression Scale (HADS). Intergroup comparisons were assessed using t-test and Mann-Whitney tests, as appropriate. Multivariate analysis was performed by a linear regression model.

Results: We enrolled 85 patients (67.1% female; mean age 65.7±12.5 years; mean disease duration 7.9±6.5 years) with the following diagnosis: 44 dermatomyositis (51.8%), 36 polymyositis (42.3%), 5 inclusion body myositis (5.9%). Among clinical features, dysphagia and sicca symptoms were found to have the greatest impact on HRQoL: in fact, dysphagia was associated with worse outcomes in all PROs (PGA p< 0.001, HAQ p< 0.001, SF36 p≤0.031, FACIT-F p< 0.001, HADS p=0.023 for anxiety and p=0.002 for depression), while sicca symptoms were found to be associated with worse scores in three of four SF36 domains of both mental and physical health (p≤0.044 and p≤0.027, respectively) and in a greater fatigue assessed by FACIT-F (p=0.006). As expected, HRQoL was significantly impaired by the coexistence of fibromyalgia (FM), which indeed determined worse scores of HAQ (p=0.031) and all SF36 domains (p≤0.021), higher fatigue levels (p=0.006) and higher levels of anxiety and depression evaluated by HADS (p=0.025 and p=0.05, respectively); also osteoporosis (OP) was found to significantly impact on PGA (p=0.027) and physical functioning and general health evaluated by SF-36 (p=0.044 and p=0.029, respectively). At multivariate analysis, among clinical variables, only dysphagia maintained a significant impact on almost all PROs (p≤0.018, except for pain and physical role domains of SF36); among comorbidities, FM had a significant impact on all PROs (p≤0.05), whereas OP had an impact only on the SF36 domains (p≤0.03).

Conclusion: Our data could help rheumatologists to focus their attention on specific clinical domains of IIMs in the perspective of preserving patients’ QoL. In particular, dysphagia and FM were found to be the main determinants of HRQoL in IIM patients, thus suggesting their better control and optimized management could significantly improve patients’ physical and psychological functioning. Moreover, OP prevention might further reduce the disease burden in this group of patients, thus ameliorating their quality of care.


Disclosures: C. Cardelli: None; S. Barsotti: None; E. Laurino: None; M. Diomedi: None; F. Fattorini: None; D. Zucchi: None; A. Tripoli: None; L. Carli: None; M. Mosca: AstraZeneca, 2, Bristol-Myers Squibb(BMS), 2, Eli Lilly, 2, GlaxoSmithKlein(GSK), 2, Otsuka, 2, UCB, 2.

To cite this abstract in AMA style:

Cardelli C, Barsotti S, Laurino E, Diomedi M, Fattorini F, Zucchi D, Tripoli A, Carli L, Mosca M. Health-Related Quality of Life in Idiopathic Inflammatory Myopathies: How to Act for Improving the Disease Burden of Patients? [abstract]. Arthritis Rheumatol. 2023; 75 (suppl 9). https://acrabstracts.org/abstract/health-related-quality-of-life-in-idiopathic-inflammatory-myopathies-how-to-act-for-improving-the-disease-burden-of-patients/. Accessed .
  • Tweet
  • Email
  • Print

« Back to ACR Convergence 2023

ACR Meeting Abstracts - https://acrabstracts.org/abstract/health-related-quality-of-life-in-idiopathic-inflammatory-myopathies-how-to-act-for-improving-the-disease-burden-of-patients/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology